News & Views
PIQUR to Develop Anti-Cancer Therapies
May 23 2013
University of Basel spin-off PIQUR Therapeutics AG, a targeted cancer therapy start-up focused on the discovery and the development of innovative anti-cancer drugs based on lipid kinase (PI3K) and mTOR inhibition, is set to make advances having recently secured financing from private investors and the Swiss Innovation Promotion Agency KTI/CTI.
Enjoying the unique support of its hosting University of Basel, both in terms of IP funding and the use of laboratories and support, the funds will be used for preclinical pharmacology and regulatory toxicology studies and the operational set-up of the company. Its location at the Rosental Biopark, which fosters exchange between different biotech companies and the neighbouring pharma companies has also helped build a unique cluster of young, talented and experienced researchers in the field of oncology , “with an an outstanding track record in science and business,” said Dr. Vladimir Cmiljanovic, CEO and co-founder of PIQUR. Selected top-experts from industry have been appointed as executives and advisors, he added.
The research group of Prof. Dr. Matthias P. Wymann, a professor at the Institute of Biochemistry and Genetics at the University of Basel, has shown how knowledge of the molecular processes involved in the development of disease can be used to develop targeted therapies.
With the University committed to translational research PIQUR offers a means of bringing such research results under licence agreements to market through potential product development. "The University is proud of PIQUR, not only for the quality of its basic research but also for the potential benefits that the new drugs offer cancer patients," said Prof. Dr. Edwin Constable, Deputy Vice Chancellor (Research) at the University of Basel.
Digital Edition
LMUK 49.7 Nov 2024
November 2024
News - Research & Events News - News & Views Articles - They’re burning the labs... Spotlight Features - Incubators, Freezers & Cooling Equipment - Pumps, Valves & Liquid Hand...
View all digital editions
Events
Nov 18 2024 Shanghai, China
Nov 20 2024 Karachi, Pakistan
Nov 27 2024 Istanbul, Turkey
Jan 22 2025 Tokyo, Japan
Jan 22 2025 Birmingham, UK